Stay updated with breaking news from Samuel Barone. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for retinal degenerative diseases, today...
/PRNewswire/ -- Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for retinal degenerative diseases, today...
Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), today announced presentations at the American Academy of Ophthalmology (AAO) 2023 Annual Meeting and Eyecelerator @ AAO 2023 taking place in San Francisco, California. Details for the presentations are as follows:
/PRNewswire/ -- Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases, announced today...
Press release content from Business Wire. The AP news staff was not involved in its creation. Gemini Therapeutics Appoints Samuel Barone, M.D., as Chief Medical Officer April 12, 2021 GMT CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 12, 2021-- Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD) and linked ocular disorders, today announced the appointment of Samuel Barone, M.D., as Gemini’s Chief Medical Officer, effective immediately. “We are thrilled to welcome Sam ...